0 126

Cited 2 times in

Long-acting FC-fusion rhGH (GX-H9) shows potential for up to twice-monthly administration in GH-deficient adults

 Cheol Ryong Ku  ;  Thierry Brue  ;  Katharina Schilbach  ;  Stanislav Ignatenko  ;  Sandor Magony  ;  Yoon-Sok Chung  ;  Byung-Joon Kim  ;  Kyu Yeon Hur  ;  Ho-Cheol Kang  ;  Jung Hee Kim  ;  Min Seon Kim  ;  Aldona Kowalska  ;  Marek Bolanowski  ;  Marek Ruchala  ;  Svetozar Damjanovic  ;  Juraj Payer  ;  Yun Jung Choi  ;  Su Jin Heo  ;  Tae Kyoung Kim  ;  MinKyu Heo  ;  Joan Lee  ;  Eun Jig Lee 
 EUROPEAN JOURNAL OF ENDOCRINOLOGY, Vol.179(3) : 169-179, 2018 
Journal Title
Issue Date
Adult ; Female ; Human Growth Hormone/administration & dosage* ; Human Growth Hormone/deficiency* ; Humans ; Immunoglobulin D ; Immunoglobulin Fc Fragments ; Immunoglobulin G ; Insulin-Like Growth Factor I/analysis ; Male ; Middle Aged ; Recombinant Fusion Proteins/administration & dosage* ; Treatment Outcome
OBJECTIVE: Hybrid Fc-fused rhGH (GX-H9) is a long-acting recombinant human growth hormone (GH) under clinical development for both adults and children with GH deficiency (GHD). We compared the safety, pharmacokinetics and pharmacodynamics of weekly and every other week (EOW) dosages of GX-H9 with those of daily GH administration in adult GHD (AGHD) patients. DESIGN: This was a randomized, open-label, active-controlled and dose-escalation study conducted in 16 endocrinology centers in Europe and Korea. METHODS: Forty-five AGHD patients with or without prior GH treatment were enrolled. Patients with prior GH treatments were required to have received the last GH administration at least 1 month prior to randomization. Subjects were sequentially assigned to treatment groups. Fifteen subjects were enrolled to each treatment group and randomly assigned to receive either GX-H9 or Genotropin (4:1 ratio). GX-H9 dosage regimens for Groups 1, 2 and 3 were 0.1 mg/kg weekly, 0.3 mg/kg EOW and 0.2 mg/kg EOW, respectively. All Genotropin-assigned subjects received 6 µg/kg Genotropin, regardless of treatment group. Main outcome analyses included measurements of serum insulin-like growth factor 1 (IGF-I), safety, pharmacokinetics, pharmacodynamics and immunogenicity. RESULTS: Mean GX-H9 peak and total exposure increased with an increase in dose after a single-dose administration. The mean IGF-I response was sustained above baseline over the intended dose interval of 168 h for the weekly and 336 h for the EOW GX-H9 groups. Safety profiles and immunogenicity were not different across the treatment groups and with Genotropin. CONCLUSIONS: GX-H9 has the potential for up to twice-monthly administration.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Ku, Cheol Ryong(구철룡) ORCID logo https://orcid.org/0000-0001-8693-9630
Lee, Eun Jig(이은직) ORCID logo https://orcid.org/0000-0002-9876-8370
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.